An open-label Phase II study of combination of TSR-042, bevacizumab, and niraparib in patients with platinum-resistant ovarian cancer (OC): Cohort A of the OPAL trial

被引：0
|
作者：
Liu, Joyce [1 ]
Gunderson, Camille [2 ]
Hendrickson, Andrea Wahner [3 ]
Ratner, Elena [4 ]
Diver, Elisabeth [5 ]
Moroney, John [6 ]
Arend, Rebecca C. [7 ]
Louie-Gao, Melinda [8 ]
Wang, Sarah [8 ]
Luptakova, Katarina [8 ]
Konecny, Gottfried E. [9 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA
[3] Mayo Clin, Dept Oncol, Rochester, MN USA
[4] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA
[5] Stanford Univ, Sch Med, Dept Obstet & Gynecol, Stanford, CA 94305 USA
[6] Univ Chicago Med, Dept Obstet & Gynecol, Chicago, IL USA
[7] Univ Alabama Birmingham, Obstet & Gynecol, Birmingham, AL USA
[8] TESARO Inc, Waltham, MA USA
[9] Univ Calif Los Angeles, Med Ctr, Dept Med, Santa Monica, CA USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-CT157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT157
引用
收藏
页数：2
相关论文
共 50 条
  • [1] An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial
    Liu, Joyce
    Gaillard, Stephanie
    Hendrickson, Andrea Wahner
    Moroney, John
    Yeku, Oladapo
    Diver, Elisabeth
    Gunderson, Camille
    Arend, Rebecca
    Ratner, Elena
    Samnotra, Vivek
    Gupta, Divya
    Evilevitch, Lena
    Wang, Sarah
    Wang, Ping
    Tang, Joseph
    Bacque, Emeline
    Liu, Xiaohong
    Konecny, Gottfried
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S17 - S18
  • [2] Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial
    Liu, Joyce F.
    Gaillard, Stephanie
    Hendrickson, Andrea E. Wahner
    Yeku, Oladapo
    Diver, Elisabeth
    Gunderson Jackson, Camille
    Arend, Rebecca
    Ratner, Elena
    Samnotra, Vivek
    Gupta, Divya
    Chung, Jon
    Zhang, Hailei
    Compton, Natalie
    Baines, Amanda
    Bacque, Emeline
    Liu, Xiaohong
    Felicetti, Brunella
    Konecny, Gottfried E.
    JCO PRECISION ONCOLOGY, 2024, 8
  • [3] Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
    Pujade-Lauraine, Eric
    Hilpert, Felix
    Weber, Beatrice
    Reuss, Alexander
    Poveda, Andres
    Kristensen, Gunnar
    Sorio, Roberto
    Vergote, Ignace
    Witteveen, Petronella
    Bamias, Aristotelis
    Pereira, Deolinda
    Wimberger, Pauline
    Oaknin, Ana
    Mirza, Mansoor Raza
    Follana, Philippe
    Bollag, David
    Ray-Coquard, Isabelle
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (13) : 1302 - +
  • [4] Efficacy and safety of chiauranib in a combination therapy in platinum-resistant or refractory ovarian cancer: a multicenter, open-label, phase Ib and II study
    Li, Jin
    Liu, Jihong
    Yin, Rutie
    Zou, Dongling
    Zheng, Hong
    Cao, Junning
    Chen, Zhendong
    Sun, Wei
    Gao, Yunong
    Zhang, Songling
    Zeng, Linjuan
    An, Ruifang
    Lu, Xianping
    Ye, Shuang
    Wu, Xiaohua
    MOLECULAR CANCER, 2024, 23 (01)
  • [5] Anlotinib plus pemetrexed in patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study
    Chen, J.
    Wei, W.
    Zheng, L.
    Li, H.
    Feng, Y.
    Wan, T.
    Huang, Q.
    Liu, G.
    Tu, H.
    Qiu, J.
    Jiang, X.
    Xiong, Y.
    Zheng, M.
    Li, J.
    Huang, H.
    Song, L.
    Liu, J.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S734 - S734
  • [6] Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
    Cannistra, Stephen A.
    Matulonis, Ursula A.
    Penson, Richard T.
    Hambleton, Julie
    Dupont, Jakob
    Mackey, Howard
    Douglas, Jeffrey
    Burger, Robert A.
    Armstrong, Deborah
    Wenham, Robert
    McGuire, William
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5180 - 5186
  • [7] Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial EDITORIAL COMMENT
    不详
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2014, 69 (07) : 402 - +
  • [8] Phase II trial of the NDC CRLX101 in combination with bevacizumab in patients with platinum-resistant ovarian cancer (PROC)
    Krasner, Carolyn
    Birrer, Michael
    Peters, Christian
    Jayaraman, Lata
    Eliasof, Scott
    Tellez, Andres
    Downing, William
    Senderowicz, Adrian
    CANCER RESEARCH, 2016, 76
  • [9] PRO-105, a phase II open-label study of NUC-1031 in patients with platinum-resistant ovarian cancer.
    Gourley, Charlie
    Dalton, Heather J.
    Banerjee, Susana N.
    Buscema, Joseph
    Lockley, Michelle
    Krell, Jonathan
    Monk, Bradley J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib plus dostarlimab in patients with platinum-resistant ovarian cancer
    Randall, L. M.
    O'Malley, D. M.
    Monk, B. J.
    Coleman, R. L.
    O'Cearbhaill, R. E.
    Gaillard, S.
    Adams, S.
    Cappuccini, F.
    Huang, M.
    Chon, H. S.
    Secord, A. A.
    Arora, S.
    Keeton, E.
    Gupta, D.
    Samnotra, V.
    Konstantinopoulos, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S646 - S647
12345